C797S
· 4 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | C797S | “Resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, particularly due to the C797S mutation, poses a significant clinical challenge.” | 0.82 | literature_variant_regex_v2 |
| variant | C797S | “Secondary mutations (e.g. 'T790M', 'C797S'), off-target effects, and resistance due to alternate pathway activation reduce the efficacy of currently available EGFR inhibitors.” | 0.82 | literature_variant_regex_v2 |
| variant | C797S | “For each class, we highlight lead compounds that achieved sub-nanomolar to low-micromolar EGFR inhibition, delineate substituent effects on kinase affinity and cellular antiproliferative activity, and discuss strategies to overcome common resistance mutations (e.g., L858R, T790M, C797S).” | 0.82 | literature_variant_regex_v2 |
| variant | C797S | “Newer mutations like C797S cause failure of Osimertinib and other EGFR TKIs belonging to the third-generation caused by the development of resistance.” | 0.82 | literature_variant_regex_v2 |